Cullinan Therapeutics (CGEM)

A central part of Cullinan’s strategy is the development of bispecific T cell engagers, engineered antibodies that bind both a disease-associated target and CD3 on T cells to redirect immune activity. Its pipeline includes CLN-978, a CD19xCD3 candidate being developed for autoimmune indications, and velinotamig, a BCMAxCD3 program also aimed at autoimmune disease. In oncology, the company is evaluating CLN-049, a FLT3xCD3 bispecific T cell engager in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.

Cullinan also develops zipalertinib, a targeted therapy candidate for non-small cell lung cancer. Alongside these clinical assets, the company maintains preclinical programs across immunology and oncology, giving it multiple potential paths for future development.

As a clinical-stage company, Cullinan’s investment profile is driven less by current product revenue and more by clinical trial progress, safety and efficacy data, regulatory milestones, partnership opportunities, and capital requirements. Its distinctive position comes from a pipeline that spans both autoimmune disorders and cancer, with several programs built around immune-cell redirection. Success depends on demonstrating that its candidates can deliver meaningful patient benefit while meeting the safety standards required for complex immune-modulating therapies.